Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXIES LUNG 301
2023-504753-12-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing belrestotug + dostarlimab with placebo + pembrolizumab (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504753-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504753-12-00.